
The Sunday Roast
The Sunday Roast
Weekly stock banter and guest CEOs in the UK small-cap space.
S12 Ep20: Midweek Takeaway with Sapan Ghai, Chief Commercial Officer of Sovereign Metals Limited (AIM:SVML) #SVML
Episode discussion: Sapan Ghai discusses Sovereign Metals' Kasiya project, DFS results, and dividend potential with Tim Carstens
Speakers’ claims: Sapan Ghai, Chief Commercial Officer of Sovereign Metals (SVML), outlines the company's Kasiya Critical Minerals Project in Malawi, which hosts the world's largest rutile and second-largest graphite deposits. He highlights the completion of a Definitive Feasibility Study (DFS) in April 2026 and the appointment of Executive Chairman Tim Carstens, citing his track record at Base Resources. Ghai emphasizes the price bifurcation for non-Chinese supply chains, noting extreme premiums for materials like yttrium. The discussion projects significant free cash flow and potential dividends that could cover the market cap within two to three years.
S12 Ep18: Sunday Roast featuring Delta Gold Technologies, Ajax Resources plc, Fulcrum Metals and Aterian PLC #DGQ #AJAX #FMET #ATN #TGR
Episode discussion: Sunday Roast S12 Ep18: Delta Gold, Ajax Resources, Fulcrum Metals, Aterian PLC, and Total Graphite
Speakers’ claims: Hosts and guests discuss market reactions to US midterm elections and detail corporate updates for five mining and technology firms. Delta Gold Technologies outlines its quantum sensing expansion and government engagement. Ajax Resources describes its Paguanta acquisition, Norwegian listing, and strategic pivot to revenue generation. Fulcrum Metals reports on pilot plant progress and uranium asset optioning. Aterian PLC highlights record tantalum sales and trading margins. Total Graphite discusses a Tanzanian acquisition and fundraise.
S12 Ep17: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS
Episode discussion: Solvonis CEO Tennyson cites patent allowance and undervaluation amid FDA feedback wait
Speakers’ claims: Anthony Tennyson, CEO of Solvonis Therapeutics, stated the US Patent Office allowed broad patent claims for ketamine treatment of behavioral addictions, covering a market of 48 million Americans with protection until 2042. He cited the $1.2 billion acquisition of Transcend by Otsuka/Abbvie as a benchmark for method-of-use patents, arguing Solvonis is undervalued relative to peers like Compass Pathways and GH Research. Tennyson outlined that the company must complete a Phase 2 program to attract pharmaceutical interest, prioritizing internal capital for O01, O02, O015, and O114 programs while seeking non-dilutive financing. The company is awaiting FDA feedback on bridging O02 to Spravato and NIDA feedback on the O015 program for methamphetamine/cocaine addiction. Tennyson expects regulatory feedback and financing progress within the next 2-4 months.